BioSpace News Archive

Albany NY, United States: An injury caused to the body by a bullet, knife, or by any sharp projectile object is known as a gunshot injury.

Albany NY, United States: A slit lamp is a diagnostic instrument commonly used by ophthalmologists and a standard tool in every ophthalmology practice.

Genentech, a member of the Roche Group, announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® and chemotherapy as an initial treatment for people with extensive-stage small cell lung cancer, did not meet its co-primary endpoint of progression-free survival.

Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced it has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company’s total financing raised to date to $213.5 million.

Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain disorders.

Transcenta Holding Limited announces the preclinical data of TST005, a bifunctional fusion protein of PD-L1/TGF-βRII, will be presented as a poster at the upcoming 2022 American Association for Cancer Research Meetings, taking place from April 8th to April 13th in New Orleans via in person or virtual attendance.

BioNTech SE reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate progress.

Design Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for degenerative genetic disorders, announced that it has completed dosing in the first single ascending dose cohort of its Phase 1 clinical trial of DT-216 in patients with Friedreich ataxia.

Bio-Thera Solutions, Ltd. announced that dosing has begun in Phase 1 clinical study to evaluate the pharmacokinetics, safety, and preliminary anti-tumor activity of BAT6026, a highly differentiated monoclonal antibody targeting OX40 with enhanced ADCC functions, in combination with BAT1308, a proprietary anti-PD-1 antibody currently in early-stage clinical trials.

NERx Biosciences , an oncology company led by John Turchi and Katherine Pawelczak, will be presenting on two pre-clinical pipeline drugs that may have a broad impact on curing two of the most common and deadly cancers: lung and breast.